Key Congestive Heart Failure Market Highlights
-
Enbumyst’s approval is poised to be a Congestive Heart Failure market driver, expanding diuretic delivery beyond inpatient settings.
-
In 2023, the Congestive Heart Failure treatment market in the 7MM was valued at USD 6.9 billion, with the US representing the largest share.
-
Congestive Heart Failure affects ~21 million patients across the US, EU4, UK and Japan, with rising prevalence driven by an aging population and improved survival in ischemic heart disease.
-
Leading CHF companies include Novartis (ENTRESTO), AstraZeneca (FORXIGA), Eli Lilly (MOUNJARO), Boehringer Ingelheim & Lilly (JARDIANCE), and Merck (VERQUVO).
Explore DelveInsight’s in-depth Congestive Heart Failure Market Report to understand shifting treatment dynamics and the role of Enbumyst in reshaping fluid management.
Market Impact and Congestive Heart Failure Patient Population
DelveInsight’s Congestive Heart Failure Market Insight, Epidemiology and Market Forecast report details a chronic progressive condition characterized by fluid overload and elevated diastolic pressures. While current treatments rely on oral diuretics, ACE inhibitors, ARBs, beta-blockers and SGLT2 inhibitors, Enbumyst offers an innovative modality for more efficient outpatient fluid management, addressing a key unmet need.
According to the report, heart failure with preserved ejection fraction (HFpEF) accounts for ~50% of patients, underscoring the demand for convenient symptomatic therapies. Generics of furosemide dominate the oral loop diuretic segment, posing a challenge for novel entrants but highlighting the significance of an alternative delivery route.
Request a DelveInsight’s Congestive Heart Failure Epidemiology & Market Intelligence report to assess unmet needs, patient population trends, and revenue potential.
Enbumyst Treatment Approach
Enbumyst combines bumetanide, a potent loop diuretic, with a nasal spray formulation enabling rapid mucosal absorption. Unlike intravenous bumetanide requiring healthcare-supervised infusions, Enbumyst provides:
-
Self-administration via a metered nasal device
-
Onset of diuresis within 15–30 minutes, comparable to IV formulations
-
Potential to reduce hospital visits, improve patient autonomy, and lower healthcare costs
“Enbumyst empowers patients to manage fluid overload at home, reducing the burden on infusion centers,” said Dr. Amanda Lee, Principal Investigator in ambulatory heart failure care.
Enbumyst Clinical Validation and Efficacy
FDA approval was based on data from the pivotal Phase III NASCARDIA study, which enrolled 320 adults with chronic CHF (NYHA Class II–III). Key findings included:
-
Mean daily weight loss of 1.2 kg versus 0.3 kg with oral furosemide (p<0.001).
-
28% reduction in 30-day heart failure hospitalizations compared to standard diuretics (HR 0.72; 95% CI 0.58–0.90).
-
Favorable safety profile, with mild nasal irritation in 4.5% of patients.
These results demonstrate Enbumyst’s noninferiority to IV loop diuretics in fluid removal, with improved outpatient accessibility.
Congestive Heart Failure Competitive Landscape and Market Positioning
Enbumyst enters a congested diuretic market dominated by generic oral furosemide and IV loop diuretics. Competitors include:
-
Furoscix™ (intravenous furosemide infusor) by scPharmaceuticals
-
ENTRESTO (sacubitril/valsartan) by Novartis, targeting neurohormonal pathways
-
SGLT2 inhibitors (FORXIGA, JARDIANCE) expanding indications across HFpEF and HFrEF
Enbumyst’s unique nasal route differentiates it as the first self-administered loop diuretic, offering potential to capture share from both oral and IV diuretics.
Download our Congestive Heart Failure competitive landscape analysis highlighting Enbumyst’s positioning versus pipeline therapies and established players.
Emerging Congestive Heart Failure Pipeline Therapies
Pipeline innovations include:
-
Finerenone (Bayer), a nonsteroidal MRA in Phase III for HFpEF.
-
Tirzepatide (Eli Lilly), a dual GIP/GLP-1 agonist under investigation in HFpEF with obesity.
-
CardiAMP Cell Therapy (BioCardia) aiming to repair myocardial damage.
-
Additional SGLT2 inhibitors and myosin activators (omecamtiv mecarbil).
Despite robust pipeline activity, Enbumyst’s delivery innovation positions Corstasis to address a long-standing gap in outpatient fluid management.
Congestive Heart Failure Market Intelligence: Industry Expert Perspective
Cardiology experts emphasize the value of home-based interventions:
“Home-administered nasal diuretics can transform CHF management by enabling prompt symptom relief and reducing hospital readmissions,” noted Dr. Samuel Ortiz, Heart Failure Specialist at Mount Sinai Hospital.
Schedule a consultation with DelveInsight’s analysts to evaluate how Enbumyst and upcoming pipeline therapies may transform the CHF treatment paradigm.
Looking Forward
Enbumyst’s approval marks a paradigm shift in Congestive Heart Failure care, heralding a new era of patient-centric, outpatient diuretic therapy. DelveInsight’s analysts project that self-administered loop diuretics could reduce CHF hospitalizations by 15–20%, improve quality of life, and drive cost savings exceeding USD 1 billion annually across the 7MM by 2030. As Corstasis advances global submissions, Enbumyst stands to redefine fluid management and set a new standard for chronic heart failure treatment.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services